Halifax Biomedical Chooses Scriptnetics for Software Development

Scriptnetics, Inc. today announced it has secured a software development contract with Halifax Biomedical, Inc. to produce clinical trial quality control software for use by medical technicians who monitor and measure the effectiveness of orthopedic surgery implants.

"This contract further expands Scriptnetics' market reach of software development into the leading edge of the healthcare industry," said Michael Milne, CEO of Scriptnetics. "We are very excited about this opportunity with Halifax Biomedical in their work with Roentgen Stereophotogrametric Analysis," RSA.

RSA is an advanced stereo medical imaging technique that utilizes two simultaneous planar x-rays to precisely monitor three dimensional migrations of total joint replacement. Scriptnetics is providing software components to monitor quality control and manage clinical trial images in Halifax Biomedical's Standardized RSA radiology suite. The HIPAA and PIPEDA compliant components to be provided by Scriptnetics include: a technician interface, dicom anonymizing, HL7 clinical trial identification tags and secure remote image transfer.

Chad Munro, CEO of Halifax Biomedical states, "Scriptnetics medical software experience has helped us move confidently with the development of our Standardized RSA radiology suite. Working with a high level, experienced software company like Scriptnetics means we can provide the very best for our customers."

About Scriptnetics, Inc.

Scriptnetics, is a global leader in software development for the medical industry. It also markets some of its own products including Medscribbler (


Halifax Biomedical Chooses Scriptnetics for Software Development



***Note This page is an Archieve of Publicly released information either through our company or another Press Release organization. We do not "fact check", "Support", nor "Dispute" any of the information provided to us. We are a distribution point and Historical press release research and search service. This information only represents the fact that at one point in time the release was distributed to 1000's of publications both online and off. PRNewsNow will not take sides in any personal or commercial disputes you have with the writer of this press release. We will defend its right to exist blindly and without regards to its political, commercial or personal implications.***